SCRIBE THERAPEUTICS INC
SCTXNASDAQ🏆 #3203 by market capUS Equity
$133.77▲ $10.70 (+8.00%)
Simulated priceTrack SCTX
Get earnings, price moves & breaking news on Telegram
24h▲ 8.0%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$373M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
72
Fair
No chart data available for SCTX.
Trading Snapshot
- Day Range
- $133.20 – $135.86
- 52-Week Range
- $15.00 – $39.60
- Volume
- $2.81B
- Avg Volume
- $2.04B
- Shares Outstanding
- 16.2M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $51M
- Last Q Revenue
- $13M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own SCTX
- ✓High-growth profile — revenue up +29.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SCRIBE THERAPEUTICS INC
SCTXFinancial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$51M▲ +32.0% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
57.1%▲ +4.0% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$4M▲ +32.0% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$4M▲ +32.0% YoY
StockOtter · stockotter.spaceAbout SCRIBE THERAPEUTICS INC
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100
Analyst Price Target
ⓘAverage Target
$161.55
▲ +20.8% Upside
High Target$197.91
Low Target$145.43
Based on 31 analysts
Latest News & Updates
🚀
CNBC·2h ago
SCRIBE THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift SCTX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
SCRIBE THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.